EP1575582A4 - Kombinationstherapie zur behandlung von akuter leukämie und myelodysplastischer syndrome - Google Patents

Kombinationstherapie zur behandlung von akuter leukämie und myelodysplastischer syndrome

Info

Publication number
EP1575582A4
EP1575582A4 EP02784400A EP02784400A EP1575582A4 EP 1575582 A4 EP1575582 A4 EP 1575582A4 EP 02784400 A EP02784400 A EP 02784400A EP 02784400 A EP02784400 A EP 02784400A EP 1575582 A4 EP1575582 A4 EP 1575582A4
Authority
EP
European Patent Office
Prior art keywords
treatment
combination therapy
myelodysplastic syndrome
acute leukemia
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02784400A
Other languages
English (en)
French (fr)
Other versions
EP1575582A1 (de
Inventor
Jay Marshall Feingold
Matthew Leigh Sherman
Mark Stanley Berger
Lance Howard Leopold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of EP1575582A1 publication Critical patent/EP1575582A1/de
Publication of EP1575582A4 publication Critical patent/EP1575582A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02784400A 2002-11-06 2002-11-06 Kombinationstherapie zur behandlung von akuter leukämie und myelodysplastischer syndrome Withdrawn EP1575582A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
EP1575582A1 EP1575582A1 (de) 2005-09-21
EP1575582A4 true EP1575582A4 (de) 2009-03-11

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02784400A Withdrawn EP1575582A4 (de) 2002-11-06 2002-11-06 Kombinationstherapie zur behandlung von akuter leukämie und myelodysplastischer syndrome

Country Status (10)

Country Link
EP (1) EP1575582A4 (de)
JP (1) JP2006508119A (de)
CN (1) CN1720044A (de)
AU (2) AU2002348178A1 (de)
BR (1) BR0215935A (de)
CA (1) CA2504611A1 (de)
CR (1) CR7804A (de)
MX (1) MXPA05004711A (de)
NO (1) NO20052009L (de)
WO (1) WO2004043461A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (de) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Anwendung von Amatoxin-Konjugaten und Phallotoxin-Konjugaten mit Makromolekülen zur Krebstherapie und Therapie von Entzündungen
KR20080030659A (ko) * 2005-07-06 2008-04-04 카니사 파마슈티컬즈, 인크. 칼리키아미신-항체 컨쥬게이트를 조스퀴다르와 조합하여사용하는 암 환자의 치료
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
PL3300601T3 (pl) * 2007-02-16 2022-05-02 Rotalec Ip Holdings Llc Ustalone stosunki leków do leczenia nowotworów hematopoetycznych i zaburzeń proliferacyjnych
EP2249831A2 (de) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Verfahren zur verwendung von (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridin-3-carbonsäure zur behandlung von vorangehenden hämatologischen erkrankungen
US20110159507A1 (en) 2008-08-29 2011-06-30 School Juridical Person The Kitasato Institute Method for detecting the drug effects of dna methylation-inhibitors
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) * 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
AR112202A1 (es) * 2017-06-22 2019-10-02 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cánceres hematológico, usos y composiciones farmacéuticas de esta
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
IL285155B2 (en) * 2019-01-28 2026-01-01 Univ Texas Therapy using metal chelators to treat cancer
CN110123825B (zh) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 一种包含去甲氧柔红霉素的药物组合物
WO2022093983A1 (en) * 2020-10-27 2022-05-05 Vor Biopharma, Inc. Compositions and methods for treating hematopoietic malignancy
WO2025214401A1 (zh) * 2024-04-12 2025-10-16 四川科伦博泰生物医药股份有限公司 抗体药物偶联物、组合物及其用途和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012347A1 (en) * 2000-08-08 2002-02-14 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012347A1 (en) * 2000-08-08 2002-02-14 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AQUINO ET AL: "Acute myelogenous leukemia", CURRENT PROBLEMS IN PEDIATRICS, MOSBY, vol. 32, no. 2, 1 February 2002 (2002-02-01), pages 50 - 58, XP005008704, ISSN: 0045-9380 *
ERIC L. SIEVERS: "Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 46, 2000, pages S18 - S22, XP002513083 *
See also references of WO2004043461A1 *
TRAIL P A ET AL: "Monoclonal antibody drug conjugates in the treatment of cancer", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 11, no. 5, 1 October 1999 (1999-10-01), pages 584 - 588, XP004257589, ISSN: 0952-7915 *

Also Published As

Publication number Publication date
WO2004043461A1 (en) 2004-05-27
NO20052009D0 (no) 2005-04-25
NO20052009L (no) 2005-06-27
CN1720044A (zh) 2006-01-11
CR7804A (es) 2008-10-29
CA2504611A1 (en) 2004-05-27
AU2002348178A1 (en) 2004-06-03
BR0215935A (pt) 2005-08-09
EP1575582A1 (de) 2005-09-21
MXPA05004711A (es) 2005-08-03
AU2010201113A1 (en) 2010-04-15
JP2006508119A (ja) 2006-03-09

Similar Documents

Publication Publication Date Title
EP1575582A4 (de) Kombinationstherapie zur behandlung von akuter leukämie und myelodysplastischer syndrome
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
IL157425A0 (en) Treatment of solid tumours with paramycin derivatives
IL164599A0 (en) Combination therapy for the treatment of cancer
GB0216321D0 (en) Therapeutic treatment
SG104356A1 (en) Absorbent body and absorbent article having the absorbent body
ZA200408767B (en) Immunoconjugates for the treatment of tumours
GB0218526D0 (en) Combination therapy
AU2003212634A8 (en) Compounds useful in the treatment of cancer
GB0201674D0 (en) Medical treatment
GB0223367D0 (en) Therapeutic treatment
GB0218879D0 (en) Medical treatment
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
GB0223854D0 (en) Therapeutic treatment
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB0223570D0 (en) Surface treatment
GB0207410D0 (en) Compounds and their therapeutic use
GB0210464D0 (en) Therapeutic treatment
AU2002304883A1 (en) Device for the treatment of tumours
AU2003296545A8 (en) Use of a trpm8-activating substance for the treatment of tumours
HUP0300990D0 (en) Synergistic combination for the prophylaxis and treatment of diabetes
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
IL164951A0 (en) The treatment of pain with lfendropil
AU2003231803A8 (en) Treatment of cancer with mefloquire

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075412

Country of ref document: HK

RAX Requested extension states of the european patent have changed

Extension state: SI

Payment date: 20050505

Extension state: RO

Payment date: 20050505

Extension state: MK

Payment date: 20050505

Extension state: LV

Payment date: 20050505

Extension state: LT

Payment date: 20050505

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEOPOLD, LANCE HOWARD

Inventor name: BERGER, MARK, STANLEY

Inventor name: SHERMAN, LEIGH, BERGER.

Inventor name: FEINGOLD, JAY, MARSHALL

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEOPOLD, LANCE HOWARD

Inventor name: BERGER, MARK, STANLEY

Inventor name: SHERMAN, MATTHEW LEIGH

Inventor name: FEINGOLD, JAY, MARSHALL

A4 Supplementary search report drawn up and despatched

Effective date: 20090210

17Q First examination report despatched

Effective date: 20090731

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100827

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075412

Country of ref document: HK